Efficacy of Intravitreal Brolucizumab Switch in Pachychoroid Neovasculopathy
Abstract Introduction This study aimed to evaluate the anatomical and functional outcomes of switching to intravitreally administered brolucizumab (Beovu®, Novartis) in patients affected by pachychoroid neovasculopathy (PNV) who were considered as non-responders to previous anti-vascular endothelial...
Saved in:
| Main Authors: | Nicolò Ribarich, Marco Battista, Lisa Checchin, Riccardo Sacconi, Francesco Bandello, Giuseppe Querques |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-07-01
|
| Series: | Ophthalmology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40123-025-01208-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Two-Years Real-World Experience of a Tertiary Center with Intravitreal Brolucizumab Switch for Treatment of Exudative Neovascular Age-Related Macular Degeneration
by: Federico Beretta, et al.
Published: (2025-04-01) -
Short-Wavelength and Infrared Autofluorescence Imaging in Pachychoroid Neovasculopathy
by: Norihiko Nakagawa, et al.
Published: (2025-04-01) -
A Case of Best Disease Accompanied by Pachychoroid Neovasculopathy
by: Figen Batıoğlu, et al.
Published: (2019-08-01) -
Clinical implication of aberrant choroidal feeding artery in type 1 macular neovasculopathy
by: Hyun Seung Yang, et al.
Published: (2025-05-01) -
Efficacy of aflibercept combined with 80% dose photodynamic therapy for pachychoroid neovasculopathy
by: Norihiko Nakagawa, et al.
Published: (2025-07-01)